Insights

Rare disease focus Dynacure is a clinical-stage biotech specializing in rare neuromuscular disorders, presenting a sales opportunity to partner for expanded antisense therapies or companion diagnostics that support DYN101 and DYN201 programs, as well as potential expansion into additional orphan disorders.

Strategic partnerships Existing collaborations with Ionis Pharmaceuticals and Nippon Shinyaku suggest a openness to co-development and regional commercialization deals; identify prospects for regional licenses, manufacturing collaboration, or joint development for new indications.

Global footprint Headquartered in Strasbourg with a US office in Philadelphia indicates a bi-national market approach; target North American and European health authorities, CROs, and contract manufacturing partners to support clinical programs and potential launches.

Financing readiness With substantial funding and a low revenue base, Dynacure may be evaluating strategic acquisitions, partnerships, or licensing to scale; present value-added collaboration models, milestone-based deals, or co-investment opportunities.

Clinical pipeline leverage DYN101 and DYN201 focus on dynamin-related pathologies offer upsell opportunities with diagnostics, patient stratification services, or companion biomarker development to strengthen future trials and potential market access discussions.

Similar companies to Dynacure

Dynacure Tech Stack

Dynacure uses 8 technology products and services including RT-qPCR, Microsoft 365, Twemoji, and more. Explore Dynacure's tech stack below.

  • RT-qPCR
    Analytics
  • Twemoji
    Font Scripts
  • Office Suites
  • Google Tag Manager
    Tag Management
  • Adobe Fonts
    Web Fonts
  • Combell
    Web Hosting
  • Nginx
    Web Servers

Media & News

Dynacure's Email Address Formats

Dynacure uses at least 1 email format:
Dynacure Email FormatsExamplePercentage
First.Last@dynacure.comJohn.Doe@dynacure.com
100%

Frequently Asked Questions

What is Dynacure's stock symbol?

Minus sign iconPlus sign icon
Dynacure is a publicly traded company; the company's stock symbol is DYCU.

What is Dynacure's official website and social media links?

Minus sign iconPlus sign icon
Dynacure's official website is dynacure.com and has social profiles on LinkedIn.

How much revenue does Dynacure generate?

Minus sign iconPlus sign icon
As of July 2026, Dynacure's annual revenue is estimated to be <$1M.

What is Dynacure's SIC code and NAICS code?

Minus sign iconPlus sign icon
Dynacure's SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Dynacure have currently?

Minus sign iconPlus sign icon
As of July 2026, Dynacure has approximately 27 employees across 1 continents, including Europe. Key team members include Owner: W. V., Scientist / Engineer: J. B. and : S. C. Explore Dynacure's employee directory with LeadIQ.

What industry does Dynacure belong to?

Minus sign iconPlus sign icon
Dynacure operates in the Biotechnology industry.

What technology does Dynacure use?

Minus sign iconPlus sign icon
Dynacure's tech stack includes RT-qPCR, Microsoft 365, Twemoji, Office 365, Google Tag Manager, Adobe Fonts, Combell and Nginx.

What is Dynacure's email format?

Minus sign iconPlus sign icon
Dynacure's email format typically follows the pattern of First.Last@dynacure.com. Find more Dynacure email formats with LeadIQ.

How much funding has Dynacure raised to date?

Minus sign iconPlus sign icon
As of July 2026, Dynacure has raised $113M in funding. The last funding round occurred on Apr 02, 2020 for $54M.
Dynacure logo

Dynacure

BiotechnologyGrand Est, France11-50 Employees

Dynacure is a clinical-stage biotechnology company aiming to develop therapies for rare diseases with limited or no treatment options. Its leading program, DYN101, is an investigational antisense therapy intended to reduce dynamin 2 protein expression to treat Myotubular and Centronuclear Myopathies, developed in collaboration with Ionis Pharmaceuticals. The company is also advancing DYN201 for Hereditary Spastic Paraplegias and building a broader research portfolio targeting other orphan disorders.

Headquartered in Strasbourg, France, with a corporate office in Philadelphia, Dynacure operates in the biotechnology research sector. In March 2023, the company announced a merger with Flamingo Therapeutics, reflecting a significant organizational development alongside its ongoing collaborations and development efforts.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
DYCU
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $113M

    Dynacure has raised a total of $113M of funding over 3 rounds. Their latest funding round was raised on Apr 02, 2020 in the amount of $54M as a Series C.

  • <$1M

    Dynacure's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.